SP
ABBV icon

Saranac Partners’s AbbVie ABBV Stock Holding History

Saranac Partners’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.46M Sell
34,561
-4,682
-12% -$1.04M 3.19% 9
2025
Q4 		$8.98M Buy
39,243
+8,164
+26% +$1.86M 3.51% 7
2025
Q3 		$7.16M Buy
31,079
+2,794
+10% +$569K 1.3% 16
2025
Q2 		$5.25M Sell
28,285
-2,641
-9% -$491K 2.79% 12
2025
Q1 		$6.48M Sell
30,926
-1,011
-3% -$197K 3.68% 4
2024
Q4 		$5.68M Buy
31,937
+1,158
+4% +$213K 3.13% 9
2024
Q3 		$6.08M Sell
30,779
-2,626
-8% -$490K 9.17% 3
2024
Q2 		$5.73M Buy
33,405
+1,274
+4% +$211K 3.41% 7
2024
Q1 		$5.85M Sell
32,131
-3,198
-9% -$551K 3.58% 5
2023
Q4 		$5.47M Sell
35,329
-19,468
-36% -$2.84M 3.61% 6
2023
Q3 		$8.17M Buy
54,797
+335
+0.6% +$49.2K 4.59% 5
2023
Q2 		$7.34M Buy
54,462
+5,371
+11% +$788K 3.89% 8
2023
Q1 		$7.82M Buy
49,091
+33,349
+212% +$5.1M 4.61% 2
2022
Q4 		$2.54M Buy
+15,742
New +$2.41M 4.61% 4

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Saranac Partners's ABBV Position: Q1 2026 in Review

Saranac Partners reduced its AbbVie (ABBV) stake by 12% in Q1 2026, selling an estimated $1.04M and leaving 34,561 shares worth $7.46M. The position accounts for 3.19% of the portfolio, ranked #9.

Saranac Partners first reported a position in ABBV in Q4 2022 and has held it in 14 quarters since. The position peaked at $8.98M in Q4 2025. 4,090 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Saranac Partners held 34,561 shares of AbbVie worth $7.46M as of Q1 2026.
  • Saranac Partners sold 4,682 AbbVie shares in Q1 2026, an estimated $1.04M.
  • AbbVie made up 3.19% of Saranac Partners's portfolio in Q1 2026, its #9 holding.
  • Saranac Partners first reported a position in AbbVie in Q4 2022 and has held it in 14 quarters since.
  • Saranac Partners's AbbVie position peaked at $8.98M in Q4 2025.
  • 4,090 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Saranac Partners's 13F filing for Q1 2026, filed 15 May 2026.